Novartis, meanwhile, handed rights to TIGIT antibody ociperlimab to BeiGene a year ago, two years after paying $300 million upfront for an option on the drug. Like PD-1/PD-L1, TIGIT is thought to ...
The auto-injector market is projected to grow at a CAGR of 8.2% from 2023 to 2033, underscoring the rising demand for these ...
Bremen (Novartis Pharma GmbH) Oct 18, 2024 Process Expert (m/f/d) – Part-time (50%) Regulär, Part time Innovative Medicines Austria Schaftenau Oct 18, 2024 Medical Scientific Liaison Manager, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback